SOLARA ACTIVE PHARMA SCIENCES
|
SOLARA ACTIVE PHARMA SCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.13 | -157.61 | -6.16 | -16.15 | 61.62 |
| CEPS(Rs) | 24.79 | -118.69 | 22.77 | 13.83 | 84.65 |
| DPS(Rs) | - | - | - | - | 7.00 |
| Book NAV/Share(Rs) | 271.04 | 258.96 | 416.43 | 423.30 | 441.06 |
| Tax Rate(%) | - | -16.08 | 50.36 | 36.02 | 0.07 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 16.07 | -7.38 | 9.27 | 6.31 | 23.87 |
| EBIT Margin(%) | 8.99 | -29.74 | 3.13 | -1.25 | 18.92 |
| Pre Tax Margin(%) | 0.04 | -37.89 | -3.10 | -7.18 | 13.70 |
| PAT Margin (%) | 0.04 | -43.99 | -1.54 | -4.60 | 13.69 |
| Cash Profit Margin (%) | 7.77 | -35.97 | 6.16 | 4.26 | 20.41 |
| Performance Ratios | |||||
| ROA(%) | 0.02 | -21.93 | -0.78 | -2.13 | 9.34 |
| ROE(%) | 0.05 | -46.64 | -1.47 | -3.75 | 17.23 |
| ROCE(%) | 6.07 | -17.29 | 1.79 | -0.67 | 15.34 |
| Asset Turnover(x) | 0.56 | 0.50 | 0.51 | 0.46 | 0.68 |
| Sales/Fixed Asset(x) | 0.68 | 0.69 | 0.80 | 0.73 | 0.98 |
| Working Capital/Sales(x) | -5.96 | -2.83 | 16.71 | 7.21 | 6.01 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.47 | 1.45 | 1.26 | 1.37 | 1.02 |
| Receivable days | 95.97 | 125.38 | 129.77 | 140.08 | 80.18 |
| Inventory Days | 96.33 | 129.95 | 143.29 | 125.26 | 64.87 |
| Payable days | 163.63 | 140.30 | 134.61 | 163.35 | 132.36 |
| Valuation Parameters | |||||
| PER(x) | 3,820.42 | - | - | - | 22.63 |
| PCE(x) | 20.68 | -2.89 | 13.29 | 44.32 | 15.18 |
| Price/Book(x) | 1.89 | 1.44 | 0.79 | 1.57 | 3.16 |
| Yield(%) | - | - | - | - | 0.50 |
| EV/Net Sales(x) | 2.21 | 1.81 | 1.51 | 2.66 | 3.35 |
| EV/Core EBITDA(x) | 13.21 | -25.96 | 13.90 | 33.72 | 13.07 |
| EV/EBIT(x) | 24.58 | -6.08 | 48.07 | -213.14 | 17.71 |
| EV/CE(x) | 1.52 | 1.21 | 0.87 | 1.32 | 2.47 |
| M Cap / Sales | 1.61 | 1.04 | 0.82 | 1.89 | 3.10 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -0.40 | -10.73 | 13.83 | -21.56 | 22.33 |
| Core EBITDA Growth(%) | 338.95 | -157.41 | 56.45 | -75.89 | 44.49 |
| EBIT Growth(%) | 130.09 | -947.28 | 385.97 | -105.17 | 58.70 |
| PAT Growth(%) | 100.10 | -2,448.13 | 61.83 | -126.33 | 93.29 |
| EPS Growth(%) | 100.09 | -2,458.12 | 61.86 | -126.21 | 44.36 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.71 | 1.07 | 0.67 | 0.67 | 0.38 |
| Current Ratio(x) | 0.77 | 0.63 | 1.08 | 1.17 | 1.34 |
| Quick Ratio(x) | 0.44 | 0.34 | 0.57 | 0.62 | 0.97 |
| Interest Cover(x) | 1.00 | -3.65 | 0.50 | -0.21 | 3.62 |
| Total Debt/Mcap(x) | 0.32 | 0.75 | 0.85 | 0.43 | 0.12 |
Compare Financial Ratios of peers of SOLARA ACTIVE PHARMA SCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SOLARA ACTIVE PHARMA SCIENCES | ₹3,259.0 Cr | -0.5% | 12% | -12% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹387,792.0 Cr | 2.3% | -0.4% | -12.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,986.0 Cr | 0% | 1.1% | 10.7% | Stock Analytics | |
| CIPLA | ₹127,126.0 Cr | 2.1% | 3.5% | -4.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹120,700.0 Cr | -1.2% | -1.7% | 4.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹109,868.0 Cr | 5.3% | 7.9% | -2% | Stock Analytics | |
SOLARA ACTIVE PHARMA SCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SOLARA ACTIVE PHARMA SCIENCES | -0.5% |
12% |
-12% |
| SENSEX | 1.5% |
1.6% |
0.4% |
You may also like the below Video Courses
